Chemistry:RU-28306

From HandWiki

RU-28306, also known as 4,α-methylene-N,N-dimethyltryptamine (4,α-methylene-DMT), is a synthetic indole alkaloid derivative which acts as a serotonin receptor agonist, with selectivity for 5-HT1 and 5-HT2 subtypes. It can be regarded as a conformationally restricted tricyclic derivative of DMT or a structurally simplified derivative of LSD. The binding affinity of racemic RU-28306 is closer to that of DMT than LSD, though with relatively higher affinity for 5-HT2 subtypes and lower for 5-HT1.[1][2] It has been sold as a designer drug and was first reported to the EMCDDA by a forensic laboratory in Slovenia in 2017.[3] It was subsequently patented by Delix Therapeutics in 2021.[4]

See also

References

  1. ↑ "Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites". Life Sciences 41 (16): 1961–9. October 1987. doi:10.1016/0024-3205(87)90749-1. PMID 3657392. 
  2. ↑ "Stereochemical Aspects of Hallucinogenesis". Biochemistry and Physiology of Substance Abuse. 3. Boca Raton, Fla.: CRC Press. 1991. pp. 1–39. ISBN 978-0-8493-4463-3. OCLC 26748320. https://bitnest.netfirms.com/external/Books/BiochemistryPhysiologySubstanceAbuse3.1. 
  3. ↑ EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA
  4. ↑ ; Lee Dunlap & Florence Wagner et al."Ergoline-like compounds for promoting neural plasticity" WO patent 2021076572, published 22 April 2021, assigned to Delix Therapeutics, Inc.and The Regents of the University of California



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:RU-28306&oldid=4308824"